10-Q: Microbot Medical Secures FDA Clearance, Boosts Capital

Sentiment:

Quarterly Report 12 November 2025 4:17 PM

Microbot Medical Inc. reports significant capital raises and FDA 510(k) clearance for its LIBERTY Endovascular Robotic Surgical System, enhancing its financial position and market readiness.

Capital raiseRaised approximately $1.1 million in January 2025 through an At-the-Market (ATM) Agreement.Secured approximately $15.6 million in gross proceeds from institutional investors in a registered direct offering in January 2025.Generated approximately $916,000 from the exercise of Series E preferred investment options in January 2025.Raised approximately $13.0 million in gross proceeds from institutional investors in a registered direct offering in February 2025.Received approximately $2.3 million from the exercise of Series E and Series F preferred investment options in April 2025.Obtained approximately $1.4 million from the exercise of Series F preferred investment options in May 2025.Collected approximately $1.3 million from the exercise of Series E, F, and G preferred investment options in June 2025.Raised approximately $12.2 million from the exercise of Series F and G preferred investment options in July 2025.Generated approximately $15.2 million from the exercise of Series E, G, H, and I preferred investment options in August 2025.Received approximately $472,500 from the exercise of Series H preferred investment options in September 2025.Obtained approximately $895,744 from the exercise of placement agent options in September 2025.Raised approximately $26.5 million in gross proceeds from an inducement transaction involving the exercise of outstanding preferred investment options in September 2025.Subsequent to the balance sheet date, raised an additional approximately $2.8 million in gross proceeds from the inducement transaction in October 2025.The company may continue to raise capital through future public and private issuances of debt and/or equity securities, including through a possible At-the-Market offering and upon the cash exercise of outstanding investment options.

Better than expectedThe company achieved a critical FDA 510(k) clearance for its LIBERTY Endovascular Robotic Surgical System, a major de-risking event for a medical device company.Liquidity significantly improved with cash and marketable securities soaring to over $80 million, providing a strong financial runway for future operations and commercialization.Successfully raised approximately $93.7 million in gross proceeds from various equity offerings and warrant exercises, demonstrating strong investor support and access to capital.Net loss per share decreased despite an increase in absolute net loss, indicating that the capital raises and operational progress are viewed positively by the market, leading to significant share issuance.

Summary

Microbot Medical Inc. reported a net loss of $3,577 thousand for the three months ended September 30, 2025, compared to $3,215 thousand for the same period in 2024.
The net loss for the nine months ended September 30, 2025, was $9,678 thousand, an increase from $8,051 thousand in the prior year period.
Basic and diluted net loss per share improved to $(0.07) for the three months and $(0.25) for the nine months ended September 30, 2025, primarily due to a significant increase in weighted average common shares outstanding.
The company achieved a major milestone with FDA 510(k) clearance for its LIBERTY Endovascular Robotic Surgical System on September 8, 2025.
Cash and cash equivalents significantly increased to $6,704 thousand as of September 30, 2025, from $3,114 thousand at December 31, 2024.
Marketable securities saw a substantial rise to $73,454 thousand as of September 30, 2025, from $2,356 thousand at December 31, 2024.
Net working capital dramatically improved to approximately $77.9 million as of September 30, 2025, from $3.4 million at December 31, 2024.
The company raised approximately $93.7 million in gross proceeds from various equity issuances and warrant exercises since January 1, 2025, including $26.5 million from an inducement transaction in September 2025 and an additional $2.8 million in October 2025.
Research and development expenses, net, decreased for the three months ended September 30, 2025, to $1,171 thousand from $2,060 thousand in 2024, but slightly increased for the nine months to $4,741 thousand from $4,646 thousand.
Sales, general and administrative expenses increased significantly to $2,690 thousand for the three months and $5,864 thousand for the nine months ended September 30, 2025, compared to $1,240 thousand and $3,549 thousand, respectively, in 2024.
Other income of $316 thousand was recorded for the nine months ended September 30, 2025, resulting from a favorable Mona litigation judgment.
Financing income, net, increased to $284 thousand for the three months and $611 thousand for the nine months ended September 30, 2025, due to interest earned on marketable securities.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the critical FDA 510(k) clearance for its flagship product, which is a major de-risking event and opens the path to commercialization. This is coupled with a significantly strengthened financial position through substantial capital raises, providing a long runway for operations. While net losses increased, these are expected for a development-stage company nearing commercialization, and the per-share loss improved due to dilution from successful capital raises. The ongoing geopolitical risks in Israel are noted but currently assessed as not materially adverse to operations.

Positives

Received FDA 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System on September 8, 2025, a critical regulatory milestone for commercialization.
Significantly strengthened liquidity and capital resources, with cash and cash equivalents increasing to $6,704 thousand and marketable securities to $73,454 thousand as of September 30, 2025.
Net working capital dramatically improved to $77.9 million, providing ample funding for operations for more than twelve months.
Successfully raised approximately $93.7 million in gross proceeds from equity offerings and warrant exercises since January 1, 2025, demonstrating strong investor confidence and access to capital markets.
Obtained ISO 13485:2016 certification for its quality management system on August 13, 2024, which supports future CE Mark approval and compliance with revised FDA regulations.
Secured a favorable judgment in the Mona litigation, resulting in $316 thousand in other income.
Entered into a collaboration agreement with Emory University to explore the integration of LIBERTY with imaging systems for autonomous endovascular procedures.
Received a new grant of approximately $630,000 from the Israeli Innovation Authority (IIA) in July 2025 to finance the development of the LIBERTY manufacturing process.

Negatives

Net loss increased to $3,577 thousand for the three months and $9,678 thousand for the nine months ended September 30, 2025, indicating continued unprofitability.
Sales, general and administrative expenses rose significantly due to new hires for commercialization readiness, salary increases, bonuses, recruitment fees, conference expenses, and marketing materials.
Net cash flows used in operating activities increased to $9,288 thousand for the nine months ended September 30, 2025, compared to $7,136 thousand in the prior year, reflecting higher operational burn.
The company has incurred cumulative losses of approximately $100.6 million since inception and has not yet generated revenues from operations.

Risks

The company expects to continue incurring additional losses for the foreseeable future due to ongoing research and development and pre-commercialization activities.
Ability to raise additional capital is dependent on market demand for the company's stock and favorable terms, which are subject to development and business risks.
Ongoing Israel-Hamas War poses risks to Israeli subcontractors, vendors, suppliers, international flights, international regard for Israeli-based companies, and potential boycotts, which could materially affect the company's Israel-based operations and ability to support clinical and regulatory activities.
The company does not have specific contingency plans for escalation or changes in the Israel-Hamas War situation.
Future capital raises from equity or equity-linked securities could result in additional dilution to shareholders.
Incurrence of debt could lead to debt service obligations and restrictive operating and financing covenants.
There is no assurance that financing will be available in the amounts needed, at the times needed, or on acceptable terms.
The telesurgery feature of the LIBERTY system is still being evaluated and is not covered under the current FDA 510(k) clearance.

Future Outlook

The company anticipates CE Mark approval for the LIBERTY Endovascular Robotic Surgical System in the second half of 2026, which would allow marketing in Europe and other regions. Management expects sales, general and administrative expenses to increase over the long-term as it expands operating activities and commercialization capabilities. The company also plans to continue research and development efforts for future versions or applications of its primary product candidate. Management believes current funds are sufficient to cover operations for more than twelve months from the filing date.

Management Comments

Management has concluded that the available funds as of the balance sheet date are sufficient to fund the company's operations for more than twelve months from the issuance date of these financial statements.
We anticipate CE Mark approval in the second half of 2026. However, we can give no assurance that we will meet this or any other projected milestones, if ever.
As of the issuance date of this Quarterly Report on Form 10-Q, we have determined that there have not been any materially adverse effects on its business or operations [due to the Israel-Hamas War], but we continue to monitor the situation, as any collapse of a cease-fire with any nation or group hostile to Israel from time to time, or any future escalation or change could result in a material adverse effect on the ability of our Israeli office to support our clinical and regulatory activities. We do not have any specific contingency plans in the event of any such escalation or change.
As of the filing date of this Quarterly Report on Form 10-Q, management believes we have sufficient funds for our operations for in excess of one year.

Industry Context

Microbot Medical operates in the rapidly evolving medical device industry, specifically focusing on robotic endoluminal surgery for minimally invasive procedures. The LIBERTY Endovascular Robotic Surgical System aims to redefine surgical robotics by offering a fully disposable, compact, and remotely operable system, potentially expanding telerobotic interventions. This positions the company to address growing demand for less invasive surgical options and improved patient outcomes, particularly in peripheral interventional radiology, with future expansion into interventional cardiology and neuroradiology. The system's design to eliminate the need for extensive capital equipment and dedicated Cath-lab rooms could offer a competitive advantage in terms of cost and accessibility compared to existing robotic systems.

Comparison to Industry Standards

The LIBERTY Endovascular Robotic Surgical System is described as the 'first-ever fully disposable robot for various endovascular interventional procedures,' which differentiates it from other robotic systems that typically require extensive capital equipment and dedicated cath-lab rooms.
The system's compact, mobile, disposable, and remotely controlled attributes are highlighted as unique characteristics that may open opportunities for telerobotic interventions, potentially serving patients with limited access to life-saving procedures, a capability not universally offered by competitors.
A research collaboration with Corewell Health demonstrated the feasibility of using the LIBERTY system for simulated cardiovascular interventional procedures across two remote sites, showcasing its telemedicine potential, although this feature is not yet FDA cleared.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Shares Increase	An amendment to the company's articles of incorporation was approved by stockholders on June 10, 2025, increasing the total number of shares of common stock authorized for issuance to 120,000,000 shares, and total authorized shares to 121,000,000 (120,000,000 common, 1,000,000 preferred).	2025-06-10	This change provides the company with greater flexibility to issue additional equity, facilitating future capital raises and employee incentive plans, but also enables further potential dilution for existing shareholders.
Omnibus Performance Award Plan Amendment	An amendment to the 2020 Omnibus Performance Award Plan was approved on June 10, 2025, increasing the number of shares of common stock authorized and reserved for issuance under the plan by 2,591,019 shares.	2025-06-10	This amendment expands the pool of shares available for equity compensation, which can be used to attract, retain, and incentivize key employees and directors, aligning their interests with shareholder value creation.

Legal Proceedings

The company was named as a defendant in a lawsuit captioned Empery Asset Master Ltd., et al. vs. Microbot Medical Inc., alleging breach of representations and warranties and fraudulent inducement related to the 2017 equity financing. This lawsuit was settled on January 26, 2024, with the company paying $2,154 thousand (cash $1,100 thousand covered by insurance, and 1,005,965 shares of restricted common stock).
In March 2025, an appellate court ruled in favor of the company in a 2019 action against Alliance Investment Management, Ltd. and Joseph Mona, compelling disgorgement of short swing profits. The company received a judgment of approximately $316 thousand, net of legal fees and expenses. A subsequent petition to the U.S. Supreme Court was denied.
On June 17, 2025, the company received a demand letter from legal counsel representing a former employee in connection with an employment-related matter. As of the filing date, no formal claim has been served, and the company believes the claims are without merit.

Stakeholder Impact

**Shareholders**: Significant dilution occurred due to numerous equity issuances and warrant exercises, increasing common stock outstanding from 19,399,513 shares at December 31, 2024, to 65,833,556 shares at September 30, 2025. However, the capital raises and FDA clearance provide a stronger financial foundation and potential for future growth, which could positively impact long-term shareholder value.
**Employees**: Increased payroll and bonuses, along with new hires to support commercialization readiness, indicate growth in the workforce and investment in human capital. Share-based compensation plans continue to incentivize employees.
**Customers (future)**: The FDA 510(k) clearance for the LIBERTY system means the product is approved for market, potentially offering a new, innovative, and minimally invasive surgical option for endovascular procedures.
**Creditors**: The substantial increase in cash, cash equivalents, and marketable securities significantly strengthens the company's balance sheet and ability to meet its obligations, reducing credit risk.
**Regulatory Authorities**: The FDA clearance and ISO 13485 certification demonstrate compliance with stringent medical device regulations, enhancing the company's standing with regulatory bodies.

Next Steps

Continue increasing commercialization capabilities for the LIBERTY Endovascular Robotic Surgical System.
Pursue CE Mark approval for the LIBERTY system, anticipated in the second half of 2026, to market the product in Europe and other regions.
Continue research and development efforts for future versions or applications of the LIBERTY system.
Evaluate the combination of LIBERTY with NovaCross products or other instruments that combine guidewire and microcatheter into a single device.
Collaborate with Emory University to explore the feasibility of integrating the LIBERTY system with an imaging system to create an autonomous robotic system for endovascular procedures.
Monitor the Israel-Hamas War situation for potential adverse effects on Israel-based activities and supply chain.

Key Dates

Date	Description
2012-06-01	Microbot Israel signed an agreement with Technion Research and Development Foundation (TRDF) for a global, exclusive, royalty-bearing license for SCS and TipCat assets.
2013-01-01	Microbot Israel began receiving grants from the Israeli Innovation Authority (IIA) for research and development.
2022-10-06	Microbot Israel purchased substantially all assets of Nitiloop Ltd., including intellectual property and technology for NovaCross devices, and assumed Nitiloop's IIA grant liabilities.
2023-10-07	The State of Israel, where Microbot's R&D operations are based, suffered a surprise attack, leading to ongoing military operations.
2024-01-26	Effective date of the settlement agreement with Empery Asset Master Ltd. and other plaintiffs, resolving a lawsuit related to the 2017 financing.
2024-02-01	Company paid 25% of the CEO's 2023 annual bonus through the grant of fully vested options.
2024-02-29	Company determined that 35,625 performance-based options granted in February 2024 had met their milestones and vested.
2024-07-01	Company entered into an amendment to the At-the-Market Offering Agreement with Wainwright, allowing for the sale of up to $4,820 thousand of common stock.
2024-08-13	Company announced receipt of ISO 13485:2016 certification for its quality management system.
2025-01-06	Company entered into Securities Purchase Agreements with institutional investors for a registered direct offering of 4,000,001 shares and concurrent private placement of Series G preferred investment options.
2025-01-07	Company entered into Securities Purchase Agreements with institutional investors for a registered direct offering of 3,788,550 shares and concurrent private placement of Series H preferred investment options.
2025-02-09	Company entered into Securities Purchase Agreements with institutional investors for a registered direct offering of 6,103,289 shares and concurrent private placement of Series I preferred investment options.
2025-03-01	An appellate court held in favor of the Company in the Mona litigation, resulting in a judgment of approximately $316 thousand.
2025-03-01	Company entered into a lease agreement for its US office.
2025-06-10	At the annual meeting of stockholders, an amendment to the company's articles of incorporation was approved, increasing authorized common stock to 120,000,000 shares. This also made Series I preferred investment options immediately exercisable.
2025-07-01	The Subsidiary entered into a lease agreement for its Israel office.
2025-07-01	The IIA approved a new grant of approximately $630,000 to further finance the development of the LIBERTY Endovascular Robotic Surgical System manufacturing process.
2025-08-01	A former advisor exercised 47,218 vested options.
2025-09-08	Company announced that the FDA granted 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System.
2025-09-14	Company entered into an inducement agreement (Letter Agreement) with certain holders of existing preferred investment options.
2025-09-16	First closing of the Inducement Transaction, where certain holders exercised existing preferred investment options for cash and received new Series J preferred investment options.
2025-09-29	Second closing of the Inducement Transaction, where a certain holder exercised existing preferred investment options for cash and received new Series J preferred investment options.
2025-10-06	Third closing of the Inducement Transaction, resulting in approximately $2,781 thousand in gross proceeds from warrant exercises.
2025-10-10	Most recent cease-fire with Hamas.
2025-11-12	Filing date of the 10-Q report, with 67,158,044 shares of Common Stock outstanding.

Recommendation

strong buy

The FDA 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System is a transformative event for Microbot Medical, validating its core technology and opening the path to commercialization in a high-growth market. This critical regulatory milestone, combined with a robust capital infusion of approximately $93.7 million since January 2025, has dramatically strengthened the company's liquidity and extended its operational runway. While the company continues to incur losses, this is typical for a development-stage medical device firm, and the significant cash position ($80M+ in cash and marketable securities) mitigates near-term financial risk. The potential for the LIBERTY system to disrupt the endovascular surgery market with its disposable, compact, and remote-controlled design, coupled with ongoing R&D and strategic collaborations, presents a compelling long-term growth opportunity. Investors should consider the strong progress and de-risking events as a clear signal for a 'strong buy' recommendation, acknowledging the inherent risks of a pre-revenue company in a competitive industry.

Keywords

Robotic Surgery, Endovascular, Medical Device, FDA Clearance, LIBERTY System, Minimally Invasive Surgery, Capital Raise, Biotechnology, Healthcare Technology, ISO 13485, NovaCross, SEC Filing, 10-Q

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.